Literature DB >> 12965910

Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia.

Silvia Fernández-Serrano1, Jordi Dorca, Mercè Coromines, Jordi Carratalà, Francesc Gudiol, Frederic Manresa.   

Abstract

In order to analyze the characteristics of the inflammatory response occurring in blood during pneumonia, we studied 38 patients with severe community-acquired pneumonia. Venous and arterial blood samples were collected at study entry and on days 1, 2, 3, 5, and 7 after inclusion. The concentrations of proinflammatory (tumor necrosis factor alpha [TNF-alpha], interleukin 1beta [IL-1beta], IL-6, and IL-8) and anti-inflammatory (IL-10) cytokines were determined in order to detect differences related to the origin of the sample, the causative organism, the clinical variables, and the final outcome of the episode. Legionella pneumonia infections showed higher concentrations of TNF-alpha, IL-6, IL-8, and IL-10. After 24 h, plasma IL-6, IL-8, and IL-10 concentrations in pneumococcal episodes increased, whereas in the same time interval, cytokine concentrations in Legionella episodes markedly decreased. The characteristics of the inflammatory response in bacteremic pneumococcal episodes were different from those in nonbacteremic episodes, as indicated by the higher plasma cytokine concentrations in the former group. Finally, our analysis of cytokine concentrations with regard to the outcome--in terms of the need for intensive care unit admittance and/or mechanical ventilation as well as mortality--suggests that there is a direct relationship between the intensity of the inflammatory response measured in blood and the severity of the episode.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965910      PMCID: PMC193876          DOI: 10.1128/cdli.10.5.813-820.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

Review 1.  International consensus conferences in intensive care medicine: Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societé de Réanimation de Langue Française, and was approved by the ATS Board of Directors, July 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

2.  Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.

Authors:  C Montón; A Torres; M El-Ebiary; X Filella; A Xaubet; J P de la Bellacasa
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

Review 4.  Breaching the blood-brain barrier.

Authors:  E Tuomanen
Journal:  Sci Am       Date:  1993-02       Impact factor: 2.142

5.  Circulating interleukin 6 and interleukin 10 in community acquired pneumonia.

Authors:  P Glynn; R Coakley; I Kilgallen; N Murphy; S O'Neill
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

6.  Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli.

Authors:  A A Creasey; P Stevens; J Kenney; A C Allison; K Warren; R Catlett; L Hinshaw; F B Taylor
Journal:  Circ Shock       Date:  1991-02

7.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids.

Authors:  G Umberto Meduri; Elizabeth A Tolley; George P Chrousos; Frankie Stentz
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

8.  Compartmentalized cytokine production within the human lung in unilateral pneumonia.

Authors:  M S Dehoux; A Boutten; J Ostinelli; N Seta; M C Dombret; B Crestani; M Deschenes; J L Trouillet; M Aubier
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

9.  Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia.

Authors:  A Ortqvist; J Hedlund; B Wretlind; A Carlström; M Kalin
Journal:  Scand J Infect Dis       Date:  1995

10.  Induction of pulmonary inflammation by components of the pneumococcal cell surface.

Authors:  E Tuomanen; R Rich; O Zak
Journal:  Am Rev Respir Dis       Date:  1987-04
View more
  44 in total

1.  Impacts of Mycoplasma loads and lung lesions on immune and hematological statuses of pigs in an eight-breed cross heterogeneous population.

Authors:  Qing Zhang; Jing Li; Tao Huang; Yifeng Zhang; Wenwu Xu; Lusheng Huang; Huashui Ai; Bin Yang
Journal:  J Anim Sci       Date:  2020-08-01       Impact factor: 3.159

Review 2.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 3.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

4.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Authors:  Kevin B Walsh; John R Teijaro; Peter R Wilker; Anna Jatzek; Daniel M Fremgen; Subash C Das; Tokiko Watanabe; Masato Hatta; Kyoko Shinya; Marulasiddappa Suresh; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

5.  Corticosteroids in the treatment of severe community-acquired pneumonia.

Authors:  Tasha D Ramsey; Sean K Gorman
Journal:  Curr Infect Dis Rep       Date:  2014-05       Impact factor: 3.725

6.  Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia.

Authors:  Jie Chao; Paula Donham; Nico van Rooijen; John G Wood; Norberto C Gonzalez
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-02       Impact factor: 6.914

7.  Vitamin D Promotes Pneumococcal Killing and Modulates Inflammatory Responses in Primary Human Neutrophils.

Authors:  Karthik Subramanian; Peter Bergman; Birgitta Henriques-Normark
Journal:  J Innate Immun       Date:  2017-02-28       Impact factor: 7.349

8.  Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.

Authors:  Silvia Gómez-Zorrilla; Francisco Morandeira; María José Castro; Fe Tubau; Elisabet Periche; Rosario Cañizares; María Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Microb Drug Resist       Date:  2016-10-18       Impact factor: 3.431

9.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

Review 10.  Alveolar hypoxia, alveolar macrophages, and systemic inflammation.

Authors:  Jie Chao; John G Wood; Norberto C Gonzalez
Journal:  Respir Res       Date:  2009-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.